Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study. European journal of heart failure Bhatt, A. S., Varshney, A. S., Nekoui, M., Moscone, A., Cunningham, J. W., Jering, K. S., Patel, P. N., Sinnenberg, L. E., Bernier, T. D., Buckley, L. F., Cook, B. M., Dempsey, J., Kelly, J., Knowles, D. M., Lupi, K., Malloy, R., Matta, L. S., Rhoten, M. N., Sharma, K., Snyder, C. A., Ting, C., McElrath, E. E., Amato, M. G., Alobaidly, M., Ulbricht, C. E., Choudhry, N. K., Adler, D. S., Vaduganathan, M. 2021; 23 (7): 1191-1201

Abstract

Implementation of guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains incomplete. Non-cardiovascular hospitalization may present opportunities for GDMT optimization. We assessed the efficacy and durability of a virtual, multidisciplinary 'GDMT Team' on medical therapy prescription for HFrEF.Consecutive hospitalizations in patients with HFrEF (ejection fraction =40%) were prospectively identified from 3 February to 1 March 2020 (usual care group) and 2 March to 28 August 2020 (intervention group). Patients with critical illness, de novo heart failure, and systolic blood pressure <90?mmHg in the preceeding 24 hs prior to enrollment were excluded. In the intervention group, a pharmacist-physician GDMT Team provided optimization suggestions to treating teams based on an evidence-based algorithm. The primary outcome was a GDMT optimization score, the sum of positive (+1 for new initiations or up-titrations) and negative therapeutic changes (-1 for discontinuations or down-titrations) at hospital discharge. Serious in-hospital safety events were assessed. Among 278 consecutive encounters with HFrEF, 118 met eligibility criteria; 29 (25%) received usual care and 89 (75%) received the GDMT Team intervention. Among usual care encounters, there were no changes in GDMT prescription during hospitalization. In the intervention group, ß-blocker (72% to 88%; P = 0.01), angiotensin receptor-neprilysin inhibitor (6% to 17%; P = 0.03), mineralocorticoid receptor antagonist (16% to 29%; P = 0.05), and triple therapy (9% to 26%; P?

View details for DOI 10.1002/ejhf.2163

View details for PubMedID 33768599